Who are raltegravir and atazanavir and ritonavir's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Raltegravir, lopinavir, ritonavir, Antiretroviral therapy, BIKTARVY Tablets (BIK).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/raltegravir-and-atazanavir-and-ritonavir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

raltegravir and atazanavir and ritonavir — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

raltegravir and atazanavir and ritonavir (raltegravir and atazanavir and ritonavir) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (INSTI + PI + booster). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (INSTI + PI + booster) HIV integrase, HIV protease Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

raltegravir and atazanavir and ritonavir (raltegravir and atazanavir and ritonavir) — Giovanni Di Perri. This is a three-drug antiretroviral combination that inhibits HIV replication through complementary mechanisms: raltegravir blocks HIV integrase, while atazanavir and ritonavir inhibit HIV protease.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
raltegravir and atazanavir and ritonavir TARGET	raltegravir and atazanavir and ritonavir	Giovanni Di Perri	marketed	Antiretroviral combination therapy (INSTI + PI + booster)	HIV integrase, HIV protease
Raltegravir, lopinavir, ritonavir	Raltegravir, lopinavir, ritonavir	Allina Health System	marketed	Antiretroviral combination therapy (integrase inhibitor + protease inhibitors)	HIV integrase, HIV protease
Antiretroviral therapy	Antiretroviral therapy	ANRS, Emerging Infectious Diseases	marketed	Combination antiretroviral therapy (multiple classes: nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors, entry inhibitors)	HIV reverse transcriptase, HIV integrase, HIV protease, HIV envelope glycoproteins (gp120/gp41), CCR5 co-receptor
BIKTARVY Tablets (BIK)	BIKTARVY Tablets (BIK)	ViiV Healthcare	phase 3	Antiretroviral combination therapy (INSTI + NRTI + NRTI)	HIV reverse transcriptase, HIV integrase, HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (INSTI + PI + booster) class)

Giovanni Di Perri · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). raltegravir and atazanavir and ritonavir — Competitive Intelligence Brief. https://druglandscape.com/ci/raltegravir-and-atazanavir-and-ritonavir. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab